Key Highlights

● The Russell 2000 fell 59.20 points to close at 2,655.11.

● The S&P SmallCap 600 was the weakest major index.

● Jobless claims rose to 203,000, above expectations.

● Vivid Seats soared on a debt-for-equity swap with lenders.

The small-cap benchmark slid alongside the blue chips and tech giants on Thursday, November 19, showing that the sell-off reached well beyond the AI trade.

No hiding place in small caps

The Russell 2000 fell 59.20 points to close at 2,655.11 on Thursday, down from 2,714.31 on Wednesday. The decline kept pace with the big indexes: the Dow Jones Industrial Average dropped 1,101.11 points, the S&P 500 lost 147.80 points and the Nasdaq Composite shed 550.69 points.

Small-cap investors sometimes hope their corner of the market can act as an alternative when megacap technology stumbles, since smaller companies tend to be more tied to the domestic economy than to the AI spending boom. Thursday dashed that hope. The S&P SmallCap 600, another small-cap gauge, fared even worse, finishing as the weakest major index.

Rates, rates, rates

The common thread across the market was interest rates. The Federal Reserve is in a hiking cycle under Chair Kevin Warsh, and minutes released Wednesday showed nearly all officials see further increases as likely needed. Futures-based pricing put a quarter-point December rise as very likely.

Higher borrowing costs are a bigger burden for small companies, which typically carry more Debt relative to their size and have less access to cheap financing than large corporations. A bout of hawkish signals tends to hit them hard.

Thursday's economic data reinforced the anxiety. Jobless claims rose to 203,000, above expectations, and continuing claims climbed to 1.763 million. The Philadelphia Fed Manufacturing index dropped to 6.3 from 20.9 while prices paid surged, a mix of weaker activity and hotter costs.

The movers inside small caps

Individual stories pulled in both directions. Warby Parker (NYSE:WRBY) sank sharply to $24.13; the stock moved with its sector and the broad sell-off. SELLAS Life Sciences (NASDAQ:SLS) fell after pricing a $150 million public offering at $13.00 a share, following a huge run-up earlier in the week on positive late-stage trial data for its leukemia treatment.

On the other side, Vivid Seats (NASDAQ:SEAT) soared after signing an agreement with lenders that would swap about $273 million of secured debt for roughly 45.8 million new shares. Existing shareholders would be left with about one-fifth of the common equity, but total debt would fall to $180 million from $387 million. "We are pleased to have reached this agreement, which provides a durable capital structure," Chief Executive Lawrence Fey said in the company's release.

The broader picture

The day's tone was set largely by Anthropic's (NASDAQ:ANT) debut on the Nasdaq. The record $81.3 billion offering priced at $83 a share, opened at $111.50 and faded to $97.17 by the close. The market turned lower around midday after the listing, and selling accelerated into the close.

"People just don't have much enthusiasm for this market, and rallies tend to bring out sellers instead of chasers," one market strategist said.

Breadth was dismal across the board. In the S&P 500, decliners swamped advancers by roughly 464 to 37. The VIX jumped 3.88 points to 28.44.

What to watch

For small caps, the Fed's December 8–9 meeting is the dominant event on the horizon, with November consumer price data following on December 10. A larger-than-expected hike would squeeze already stretched borrowers further. In the near term, the November 25 jobless claims report will test whether the labor market is softening. Investors will also watch whether Vivid Seats' restructuring and similar balance-sheet moves become a theme as smaller companies adjust to higher rates.